# A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

> **NCT02395601** · PHASE1 · COMPLETED · sponsor: **Constellation Pharmaceuticals** · enrollment: 41 (estimated)

## Conditions studied

- B-Cell Lymphoma

## Interventions

- **DRUG:** CPI-1205

## Key facts

- **NCT ID:** NCT02395601
- **Lead sponsor:** Constellation Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02395601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02395601, "A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02395601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*